193 related articles for article (PubMed ID: 35306594)
1. Inactivated SARS-CoV-2 vaccine in primary Sjögren's syndrome: humoral response, safety, and effects on disease activity.
Pasoto SG; Halpern ASR; Guedes LKN; Ribeiro ACM; Yuki ENF; Saad CGS; da Silva CAA; de Vinci Kanda Kupa L; Villamarín LEB; de Oliveira Martins VA; Martins CCMF; Deveza GBH; Leon EP; Bueno C; Pedrosa TN; Santos REB; Soares R; Aikawa NE; Bonfa E
Clin Rheumatol; 2022 Jul; 41(7):2079-2089. PubMed ID: 35306594
[TBL] [Abstract][Full Text] [Related]
2. Systemic autoimmune myopathies: a prospective phase 4 controlled trial of an inactivated virus vaccine against SARS-CoV-2.
Shinjo SK; de Souza FHC; Borges IBP; Dos Santos AM; Miossi R; Misse RG; Medeiros-Ribeiro AC; Saad CGS; Yuki EFN; Pasoto SG; Kupa LVK; Ceneviva C; Seraphim JC; Pedrosa TN; Vendramini MBG; Silva CA; Aikawa NE; Bonfá E
Rheumatology (Oxford); 2022 Aug; 61(8):3351-3361. PubMed ID: 34664616
[TBL] [Abstract][Full Text] [Related]
3. Immunogenicity, safety, and antiphospholipid antibodies after SARS-CoV-2 vaccine in patients with primary antiphospholipid syndrome.
Signorelli F; Balbi GGM; Aikawa NE; Silva CA; Kupa LVK; Medeiros-Ribeiro AC; Yuki EF; Pasoto SG; Saad CG; Borba EF; Seguro LPC; Pedrosa T; Oliveira VAA; Costa ALCS; Ribeiro CT; Santos REB; Andrade DCO; Bonfá E
Lupus; 2022 Jul; 31(8):974-984. PubMed ID: 35593174
[TBL] [Abstract][Full Text] [Related]
4. Impact of Distinct Therapies on Antibody Response to SARS-CoV-2 Vaccine in Systemic Lupus Erythematosus.
Yuki EFN; Borba EF; Pasoto SG; Seguro LP; Lopes M; Saad CGS; Medeiros-Ribeiro AC; Silva CA; de Andrade DCO; Kupa LVK; Betancourt L; Bertoglio I; Valim J; Hoff C; Formiga FFC; Pedrosa T; Kallas EG; Aikawa NE; Bonfa E
Arthritis Care Res (Hoboken); 2022 Apr; 74(4):562-571. PubMed ID: 34806342
[TBL] [Abstract][Full Text] [Related]
5. Two-week methotrexate discontinuation in patients with rheumatoid arthritis vaccinated with inactivated SARS-CoV-2 vaccine: a randomised clinical trial.
Araujo CSR; Medeiros-Ribeiro AC; Saad CGS; Bonfiglioli KR; Domiciano DS; Shimabuco AY; Silva MSR; Yuki EFN; Pasoto SG; Pedrosa T; Kupa LVK; Zou G; Pereira RMR; Silva CA; Aikawa NE; Bonfa E
Ann Rheum Dis; 2022 Jun; 81(6):889-897. PubMed ID: 35193873
[TBL] [Abstract][Full Text] [Related]
6. SARS-CoV-2 vaccine in patients with systemic sclerosis: impact of disease subtype and therapy.
Sampaio-Barros PD; Medeiros-Ribeiro AC; Luppino-Assad AP; Miossi R; da Silva HC; Yuki EFVN; Pasoto SG; Saad CGS; Silva CA; Kupa LVK; Deveza GBH; Pedrosa TN; Aikawa NE; Bonfá E
Rheumatology (Oxford); 2022 Jun; 61(SI2):SI169-SI174. PubMed ID: 34894235
[TBL] [Abstract][Full Text] [Related]
7. Anti-SARS-CoV-2 inactivated vaccine in patients with ANCA-associated vasculitis: Immunogenicity, safety, antibody decay and the booster dose.
Pereira RMR; Dagostin MA; Caparbo VF; Sales LP; Pasoto SG; Silva CA; Yuki EFN; Saad CGS; Medeiros-Ribeiro AC; Kupa LVK; Fusco SRG; Martins VAO; Martins CCMF; Barbas CV; Shinjo SK; Aikawa NE; Bonfa E
Clinics (Sao Paulo); 2023; 78():100150. PubMed ID: 36529052
[TBL] [Abstract][Full Text] [Related]
8. Immunogenicity and safety of the CoronaVac inactivated vaccine in patients with autoimmune rheumatic diseases: a phase 4 trial.
Medeiros-Ribeiro AC; Aikawa NE; Saad CGS; Yuki EFN; Pedrosa T; Fusco SRG; Rojo PT; Pereira RMR; Shinjo SK; Andrade DCO; Sampaio-Barros PD; Ribeiro CT; Deveza GBH; Martins VAO; Silva CA; Lopes MH; Duarte AJS; Antonangelo L; Sabino EC; Kallas EG; Pasoto SG; Bonfa E
Nat Med; 2021 Oct; 27(10):1744-1751. PubMed ID: 34331051
[TBL] [Abstract][Full Text] [Related]
9. Immunogenicity and safety of COVID-19 vaccination in patients with primary Sjögren's syndrome.
Verstappen GM; de Wolff L; Arends S; Heiermann HM; van Sleen Y; Visser A; Terpstra JH; Diavatopoulos DA; van der Heiden M; Vissink A; van Baarle D; Kroese FGM; Bootsma H
RMD Open; 2022 Apr; 8(1):. PubMed ID: 35414631
[TBL] [Abstract][Full Text] [Related]
10. Immunogenicity decay and case incidence six months post Sinovac-CoronaVac vaccine in autoimmune rheumatic diseases patients.
Silva CA; Medeiros-Ribeiro AC; Kupa LVK; Yuki EFN; Pasoto SG; Saad CGS; Fusco SRG; Pereira RMR; Shinjo SK; Halpern ASR; Borba EF; Souza FHC; Guedes LKN; Miossi R; Bonfiglioli KR; Domiciano DS; Shimabuco AY; Andrade DCO; Seguro LPC; Fuller R; Sampaio-Barros PD; Assad APL; Moraes JCB; Goldenstein-Schainberg C; Giardini HAM; Silva HC; Martins VAO; Villamarin LEB; Novellino RS; Sales LP; Araújo CSR; Silva MSR; Filho DMN; Lopes MH; Duarte AJS; Kallas EG; Aikawa NE; Bonfa E
Nat Commun; 2022 Oct; 13(1):5801. PubMed ID: 36192386
[TBL] [Abstract][Full Text] [Related]
11. Immunogenicity and safety of two doses of the CoronaVac SARS-CoV-2 vaccine in SARS-CoV-2 seropositive and seronegative patients with autoimmune rheumatic diseases in Brazil: a subgroup analysis of a phase 4 prospective study.
Aikawa NE; Kupa LVK; Pasoto SG; Medeiros-Ribeiro AC; Yuki EFN; Saad CGS; Pedrosa T; Fuller R; Shinjo SK; Sampaio-Barros PD; Andrade DCO; Pereira RMR; Seguro LPC; Valim JML; Waridel F; Sartori AMC; Duarte AJS; Antonangelo L; Sabino EC; Menezes PR; Kallas EG; Silva CA; Bonfa E
Lancet Rheumatol; 2022 Feb; 4(2):e113-e124. PubMed ID: 34901885
[TBL] [Abstract][Full Text] [Related]
12. Safety and immunogenicity of CoronaVac in people living with HIV: a prospective cohort study.
Netto LC; Ibrahim KY; Picone CM; Alves APPS; Aniceto EV; Santiago MR; Parmejani PSS; Aikawa NE; Medeiros-Ribeiro AC; Pasoto SG; Yuki EFN; Saad CGS; Pedrosa T; Lara AN; Ceneviva C; Bonfa E; Kallas EG; Avelino-Silva VI
Lancet HIV; 2022 May; 9(5):e323-e331. PubMed ID: 35338835
[TBL] [Abstract][Full Text] [Related]
13. Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study.
Costa Clemens SA; Weckx L; Clemens R; Almeida Mendes AV; Ramos Souza A; Silveira MBV; da Guarda SNF; de Nobrega MM; de Moraes Pinto MI; Gonzalez IGS; Salvador N; Franco MM; de Avila Mendonça RN; Queiroz Oliveira IS; de Freitas Souza BS; Fraga M; Aley P; Bibi S; Cantrell L; Dejnirattisai W; Liu X; Mongkolsapaya J; Supasa P; Screaton GR; Lambe T; Voysey M; Pollard AJ;
Lancet; 2022 Feb; 399(10324):521-529. PubMed ID: 35074136
[TBL] [Abstract][Full Text] [Related]
14. Strong response after fourth dose of mRNA COVID-19 vaccine in autoimmune rheumatic diseases patients with poor response to inactivated vaccine.
Aikawa NE; Kupa LVK; Silva CA; Saad CGS; Pasoto SG; Yuki EFN; Fusco SRG; Shinjo SK; Andrade DCO; Sampaio-Barros PD; Pereira RMR; Chasin ACS; Shimabuco AY; Luppino-Assad AP; Leon EP; Lopes MH; Antonangelo L; Medeiros-Ribeiro AC; Bonfa E
Rheumatology (Oxford); 2022 Dec; 62(1):480-485. PubMed ID: 35639644
[TBL] [Abstract][Full Text] [Related]
15. Effect of an exercise bout before the booster dose of an inactivated SARS-CoV-2 vaccine on immunogenicity in immunocompromised patients.
Gualano B; Saad CGS; Sieczkowska SM; Lemes ÍR; da Silva RP; Pinto AJ; Mazzolani BC; Smaira FI; Gil S; Oliveira-Junior G; Aikawa NE; Medeiros-Ribeiro AC; Silva CA; Yuki EFN; Pasoto SG; Pereira RMR; Shinjo SK; Andrade DCO; Sampaio-Barros PD; Roschel H; Bonfa E
J Appl Physiol (1985); 2022 Mar; 132(3):682-688. PubMed ID: 35142560
[TBL] [Abstract][Full Text] [Related]
16. Association between physical activity and immunogenicity of an inactivated virus vaccine against SARS-CoV-2 in patients with autoimmune rheumatic diseases.
Gualano B; Lemes IR; Silva RP; Pinto AJ; Mazzolani BC; Smaira FI; Sieczkowska SM; Aikawa NE; Pasoto SG; Medeiros-Ribeiro AC; Saad CGS; Yuki EFN; Silva CA; Swinton P; Hallal PC; Roschel H; Bonfa E
Brain Behav Immun; 2022 Mar; 101():49-56. PubMed ID: 34954325
[TBL] [Abstract][Full Text] [Related]
17. Safety and immunogenicity of inactive vaccines as booster doses for COVID-19 in Türkiye: A randomized trial.
Omma A; Batirel A; Aydin M; Yilmaz Karadag F; Erden A; Kucuksahin O; Armagan B; Güven SC; Karakas O; Gokdemir S; Altunal LN; Buber AA; Gemcioglu E; Zengin O; Inan O; Sahiner ES; Korukluoglu G; Sezer Z; Ozdarendeli A; Kara A; Ates I
Hum Vaccin Immunother; 2022 Nov; 18(6):2122503. PubMed ID: 36315843
[TBL] [Abstract][Full Text] [Related]
18. Safety and immunogenicity of inactivated COVID-19 vaccine in patients with metabolic syndrome: A cross-sectional observational study.
Guo Q; Yang L; Peng R; Gao T; Chu X; Jiang D; Ke D; Ren H
Front Public Health; 2022; 10():1067342. PubMed ID: 36620297
[TBL] [Abstract][Full Text] [Related]
19. Safety and immunogenicity of inactivated COVID-19 vaccine in health care workers.
Benjamanukul S; Traiyan S; Yorsaeng R; Vichaiwattana P; Sudhinaraset N; Wanlapakorn N; Poovorawan Y
J Med Virol; 2022 Apr; 94(4):1442-1449. PubMed ID: 34783049
[TBL] [Abstract][Full Text] [Related]
20. Robust immunogenicity to the H3N2 component of influenza A vaccine in primary Sjögren syndrome.
Pasoto SG; Borba EF; Formiga FFC; do Nascimento Pedrosa T; Aikawa NE; de Siqueira MAMT; Capão ASV; de Proença ACT; Fuller R; Yuki EFN; Leon EP; de Oliveira Martins VA; Lopes MH; da Silva Duarte AJ; da Silva CAA; Bonfa E
Clin Rheumatol; 2023 Sep; 42(9):2419-2425. PubMed ID: 37306813
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]